{"id":"NCT02600611","sponsor":"Motif Bio","briefTitle":"Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1","officialTitle":"A Phase 3, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of ABSSSI: REVIVE-1","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-01","primaryCompletion":"2017-01-30","completion":"2017-01-30","firstPosted":"2015-11-09","resultsPosted":"2018-06-19","lastUpdate":"2018-06-19"},"enrollment":600,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Skin Structures and Soft Tissue Infections"],"interventions":[{"type":"DRUG","name":"iclaprim","otherNames":["MTF-100"]},{"type":"DRUG","name":"vancomycin","otherNames":["Vancocin"]}],"arms":[{"label":"iclaprim","type":"EXPERIMENTAL"},{"label":"vancomycin","type":"ACTIVE_COMPARATOR"}],"summary":"This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin for the treatment of skin and skin structure infections.","primaryOutcome":{"measure":"â‰¥20% Reduction in Lesion Size at 48 to 72 Hours Compared to Baseline in All Randomized Patients.","timeFrame":"Baseline and 48-72 hours after first dose of study drug","effectByArm":[{"arm":"Iclaprim","deltaMin":80.9,"sd":null},{"arm":"Vancomycin","deltaMin":81,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":56,"countries":["United States","Bulgaria","Chile","Colombia","Germany","Latvia","Peru","Poland","Puerto Rico","Ukraine"]},"refs":{"pmids":["29783024","29281036"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":298},"commonTop":["Adverse effects"]}}